Dimensional Fund Advisors LP grew its stake in Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 60.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 215,265 shares of the company's stock after acquiring an additional 80,905 shares during the period. Dimensional Fund Advisors LP owned 0.38% of Design Therapeutics worth $1,328,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Barclays PLC boosted its stake in shares of Design Therapeutics by 34.2% during the 3rd quarter. Barclays PLC now owns 96,635 shares of the company's stock worth $520,000 after acquiring an additional 24,602 shares during the period. JPMorgan Chase & Co. boosted its position in Design Therapeutics by 186.9% during the third quarter. JPMorgan Chase & Co. now owns 40,687 shares of the company's stock worth $219,000 after purchasing an additional 26,503 shares during the period. China Universal Asset Management Co. Ltd. bought a new position in Design Therapeutics during the fourth quarter worth $74,000. Rhumbline Advisers increased its holdings in shares of Design Therapeutics by 4.7% in the fourth quarter. Rhumbline Advisers now owns 52,932 shares of the company's stock valued at $327,000 after purchasing an additional 2,365 shares during the last quarter. Finally, Palumbo Wealth Management LLC raised its position in shares of Design Therapeutics by 48.7% in the fourth quarter. Palumbo Wealth Management LLC now owns 54,696 shares of the company's stock valued at $337,000 after purchasing an additional 17,922 shares during the period. Institutional investors and hedge funds own 56.64% of the company's stock.
Design Therapeutics Stock Performance
Shares of DSGN stock traded up $0.02 during midday trading on Monday, hitting $3.53. 54,858 shares of the company were exchanged, compared to its average volume of 187,018. Design Therapeutics, Inc. has a 52 week low of $2.60 and a 52 week high of $7.77. The firm has a market capitalization of $200.39 million, a P/E ratio of -4.15 and a beta of 1.77. The firm's 50 day moving average price is $3.88 and its two-hundred day moving average price is $4.88.
Design Therapeutics (NASDAQ:DSGN - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.03). Analysts expect that Design Therapeutics, Inc. will post -0.91 EPS for the current year.
Design Therapeutics Company Profile
(
Free Report)
Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.
See Also
Before you consider Design Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Design Therapeutics wasn't on the list.
While Design Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
